News | Renal Denervation | August 31, 2017

SPYRAL HTN-OFF MED Study Results Show Efficacy, Safety of Renal Denervation

Late-breaking ESC results encourage Medtronic to move forward with renal denervation pivotal trial

SPYRAL HTN-OFF MED Study Results Show Efficacy, Safety of Renal Denervation

August 31, 2017 — Medtronic plc announced its intent to move forward with a new renal denervation pivotal trial following positive first results from a sham-controlled study in patients with high blood pressure. Investigators of the SPYRAL HTN-OFF MED Study found statistically significant and clinically important blood pressure reductions in the patients treated with renal denervation (RDN) across both office and ambulatory systolic and diastolic measurements. The data in the first 80 patients enrolled in the study at three months were presented in a late-breaking clinical trial session at the European Society of Cardiology (ESC) meeting, Aug. 26-30 in Barcelona, Spain and published simultaneously in The Lancet.

“Based on the clinical results presented at ESC, we are confident that the SPYRAL HTN-OFF MED Study has successfully demonstrated the treatment effect of RDN,” said co-principal investigator (PI) and presenter of the data at ESC, Prof. Michael Böhm, M.D., Ph.D., chairman, Department of Internal Medicine, University of Saarland in Homburg/Saar, Germany. “With consistent and significant drops across ambulatory and office-based blood pressure — including both systolic and diastolic measurements — we are confident to be moving forward with a pivotal trial so that doctors and patients may have an alternative approach to lowering blood pressure.”

The initial three-month data found that patients who underwent renal denervation had their office systolic blood pressure (OSBP) decline an average 10 mm Hg, resulting in a 7.7 mm Hg difference with the patients in the sham control arm (p=0.016), and their diastolic blood pressure declined an average 5.3 mm Hg, resulting in a 4.9 mm Hg difference with the sham control arm (p=0.008). With a systolic blood pressure difference of 7.7 mm Hg between the two groups, a recent meta-analysis published in The Lancet associated that decrease with a relative risk reduction of approximately 20 percent for major cardiovascular events, including heart attack and stroke.

In SPYRAL HTN OFF-MED renal denervation patients, the 24-hour systolic ambulatory blood pressure (ABPM) declined 5.5 mm Hg, resulting in a 5 mm Hg difference from the sham control arm (p=0.041), and the diastolic AMBP declined 4.8 mm Hg, resulting in a 4.4 mm Hg difference from the sham control arm (p=0.002). Additionally, there were no reported cases of new or worsening renal failure, vascular complications or other major adverse events, confirming the safety of the RDN procedure — even with a revised procedural approach that extended ablations into the kidney’s branch arteries and an increase in total number of ablations compared with previous RDN trials.

“After SYMPLICITY HTN-3, we learned a lot about the procedure itself, medication adherence and which patients may have less response to the RDN procedure — these insights have been incorporated into the revised clinical approach in the SPYRAL HTN program,” said co-PI David Kandzari, M.D., director of interventional cardiology and chief scientific officer, Piedmont Heart Institute in Atlanta, Ga. “With this new approach and protocol design, coupled with new technology that allows more consistent circumferential treatment and easier access into the distal anatomy, based on these compelling results we are confident that we’ve appropriately addressed the issues in previous renal denervation trials.”

The SPYRAL HTN-OFF MED Study evaluated RDN in the absence of any antihypertensive medications compared to a sham-controlled population to isolate its effect on blood pressure reduction. The study enrolled 353 patients who were either drug-naïve or willing to discontinue medication for four months, with mild-to-moderate hypertension (OSBP equal to or more than 150 mm Hg and less than 180 mm Hg) at 24 centers in the U.S., Europe, Japan and Australia. Prior to randomization, patients were required to stop taking their antihypertensive medication during a period of three to four weeks, known as a medication washout. During the washout period and the three months following randomization, patients were monitored to ensure their blood pressure would not exceed 180mm Hg.

“These results are extremely encouraging for the more than 50 percent of hypertension patients who become non-adherent to their medications within one year of initiating therapy,” said co-PI Raymond Townsend, M.D., director of the hypertension program, University of Pennsylvania. “The societal implications are potentially huge as well, as high blood pressure contributes more than 500 billion dollars in direct costs to our healthcare systems globally.”

Unlike SYMPLICITY HTN-3, where patients self-reported adherence, and change in medications occurred among 40 percent of patients, the SPYRAL HTN-OFF MED Study limited that variability, as patients remained off their medication throughout the duration of the study as confirmed by serum and urine testing for antihypertensive medication. Additionally, the aftermath of SYMPLICITY HTN-3 revealed new anatomical insights showing that renal nerves are easier to access when the catheter treats the renal artery segments located close to the kidney. While SYMPLICITY HTN-3 only averaged five ablations in the main renal artery and no ablations in the branch arteries, the flexible design and low profile of the investigational Symplicity Spyral system achieved an average of 10 main renal artery and 13 branch artery ablations per kidney.

The SPYRAL HTN-OFF MED study is part of the SPYRAL HTN Global Clinical Trial Program and accompanies the SPYRAL HTN-ON MED study as two global, prospective, randomized, sham-controlled trials conducted simultaneously by hypertension experts and experienced proceduralists to investigate the impact of renal denervation both in the absence of and in the presence of antihypertensive medications. The clinical program utilizes Medtronic's next-generation renal denervation technology, composed of the flexible, 6 Fr guide catheter-compatible, Symplicity Spyral multi-electrode renal denervation catheter and Symplicity G3 renal denervation RF (radiofrequency) generator.

The Symplicity Spyral system is investigational in the United States and Japan.

Watch the VIDEO "Device Therapies to Treat Hypertension," an interview with Krishna Rocha-Singh, M.D., at TCT 2016.

Read the article "Medtronic Announces Spyral HTN Global Clinical Trial Program for Renal Denervation."

For more information: www.medtronic.com

Related Content

Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
Overlay Init